Global Phase 3 Hematology Medical Strategy Lead

Kaye/Bassman International; Boston (MA); Vor Ort; USD 350.000 - 550.000; Vollzeit

Zusammenfassung

Kaye/Bassman International is leading a high-visibility search for an Executive Medical Director / Global Clinical Lead to drive a late-stage Phase 3 hematology program in myeloid malignancies (AML/MDS/MPN) for a global biopharma. The role requires a hematologist-oncologist with Phase 3 leadership to own clinical strategy end-to-end, including FDA interactions and Advisory Committee exposure.

You will lead a global development team across the US, EU, and Asia, make go/no-go and labeling

Qualifikationen

• MD or MD/PhD (U.S. clinical training preferred, not required).
• 10+ years in pharmaceutical/biotech clinical research, including Phase 1–4 development.
• Phase 3 leadership experience in hematology/oncology (AML/MDS/MPN) preferred.

Aufgaben

• Clinical strategy for a Phase 3 program in myeloid malignancies, from pivotal execution through registration.
• Lead a global development team across the US, EU, and Asia.
• Make go/no-go and labeling-critical decisions.
• Interact with FDA and other health authorities, including Advisory Committee preparation.

Kenntnisse

Executive leadership

Global development leadership

Regulatory interactions

Cross-functional collaboration

Ausbildung

MD or MD/PhD

Jobbeschreibung

Kaye/Bassman International is leading a high-visibility search for an Executive Medical Director / Global Clinical Lead to drive a late-stage Phase 3 hematology program in myeloid malignancies (AML/MDS/MPN) for a global biopharma. The role requires a hematologist-oncologist with Phase 3 leadership to own clinical strategy end-to-end, including FDA interactions and Advisory Committee exposure.

You will lead a global development team across the US, EU, and Asia, make go/no-go and labeling